Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome

First Posted Date: 2006-01-04

Last Posted Date: 2008-03-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT00271804

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

First Posted Date: 2005-12-15

Last Posted Date: 2008-01-28

Lead Sponsor: University of Virginia

Target Recruit Count: 46

Registration Number: NCT00265928

Locations: 🇺🇸
University of Virginia Cancer Center at UV Health System, Charlottesville, Virginia, United States

Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bortezomib
Drug: gemcitabine hydrochloride

First Posted Date: 2005-12-07

Last Posted Date: 2016-05-09

Lead Sponsor: University of Rochester

Target Recruit Count: 18

Registration Number: NCT00262860

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Bortezomib in Treating Patients With Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: bortezomib

First Posted Date: 2005-12-07

Last Posted Date: 2016-05-09

Lead Sponsor: University of Rochester

Target Recruit Count: 8

Registration Number: NCT00262873

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Phase 2

Conditions: Lymphoma, Mantle-Cell

First Posted Date: 2005-12-05

Last Posted Date: 2006-10-18

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 16

Registration Number: NCT00261612

Locations: 🇦🇹
Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology, Vienna, Austria

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Dietary Supplement: ascorbic acid
Drug: arsenic trioxide
Drug: bortezomib
Drug: dexamethasone
Drug: thalidomide
Drug: Aspirin

First Posted Date: 2005-11-24

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00258245

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

Phase 4

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-11-22

Last Posted Date: 2008-02-11

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Registration Number: NCT00257114

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2005-11-09

Last Posted Date: 2016-04-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00250926

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States